Lumida
/LXRX
⌘K
Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

LXRX
$2.39USD+6.70%+0.15 today

MARKET CAP

1.1B

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

In a Stage 2 advancing market within a long-term uptrend, medium-term bias remains bullish supported by persistent higher highs/lows and rising moving averages; short-term timing is favorable as price pulls back and holds the rising 9 and 21 EMAs, warranting a Buy Now stance at the EMA support zone.

  • Full-year 2025 revenue $49.8M, up 720% since 2022
  • Licensing revenue of $17.5M from Novo Nordisk due H2 2026
  • 2025 net loss of $50.3M highlights persistent profitability issues
Full analysis →
Insider Trades26 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Feb 28, 2026SellLXRXSuma GopinathanSVP, Discovery24,338$1.47$1.1B-10.82%+139.00%$35.8K-7.46%Stalk
Feb 28, 2026SellLXRXRachel Yap MartensSVP, Partnerships & Corp Strat35,826$1.47$1.1B-10.82%+139.00%$52.7K-17.80%Stalk
Feb 28, 2026SellLXRXScott M CoianteSVP, Chief Financial Officer54,881$1.47$1.1B-10.82%+139.00%$80.7K-11.42%Stalk
Feb 28, 2026SellLXRXWendy McdermottSVP, Human Resources68,107$1.47$1.1B-10.82%+139.00%$100.1K-9.91%Stalk
Feb 28, 2026SellLXRXLisa DefrancescoSVP, IR and Corp Comm74,572$1.47$1.1B-10.82%+139.00%$109.6K-16.59%Stalk
Feb 28, 2026SellLXRXBrian T CrumSVP, General Counsel & Secr.105,019$1.47$1.1B-10.82%+139.00%$154.4K-11.13%Stalk
Feb 28, 2026SellLXRXCraig B GranowitzSVP, Chief Medical Officer109,098$1.47$1.1B-10.82%+139.00%$160.4K-11.97%Stalk
Feb 28, 2026SellLXRXMichael ExtonChief Executive Officer204,831$1.47$1.1B-10.82%+139.00%$301.1K-13.57%Stalk
Feb 28, 2025SellLXRXLisa DefrancescoSVP, IR and Corp Comm9,096$0.67$1.1B-10.82%+139.00%$6.1K-12.29%Stalk
Feb 28, 2025SellLXRXKristen AlexanderVP, Finance and Accounting17,862$0.67$1.1B-10.82%+139.00%$12.0K-11.91%Stalk
Feb 28, 2025SellLXRXWendy McdermottSVP, Human Resources30,004$0.67$1.1B-10.82%+139.00%$20.1K-10.57%Stalk
Feb 28, 2025SellLXRXAlan J MainEVP, Innov & Chem Sciences43,434$0.67$1.1B-10.82%+139.00%$29.1K-7.87%Stalk
Feb 28, 2025SellLXRXBrian T CrumSVP, General Counsel & Secr.45,622$0.67$1.1B-10.82%+139.00%$30.6K-9.53%Stalk
Feb 28, 2025SellLXRXCraig B GranowitzSVP, Chief Medical Officer65,308$0.67$1.1B-10.82%+139.00%$43.8K-17.66%Stalk
Feb 28, 2024SellLXRXKristen AlexanderVP, Finance and Accounting11,793$2.62$1.1B-10.82%+139.00%$30.9K-11.55%Stalk
Feb 28, 2024SellLXRXWendy McdermottVP, Human Resources22,425$2.62$1.1B-10.82%+139.00%$58.8K-15.00%Stalk
Feb 28, 2024SellLXRXKenneth B. Kassler-TaubSVP, Regulatory & QA24,353$2.62$1.1B-10.82%+139.00%$63.8K-8.69%Stalk
Feb 28, 2024SellLXRXAlan J MainEVP, Innov & Chem Sciences24,408$2.62$1.1B-10.82%+139.00%$63.9K-6.57%Stalk
Feb 28, 2024SellLXRXBrian T CrumSVP, General Counsel & Secr.25,604$2.62$1.1B-10.82%+139.00%$67.1K-8.65%Stalk
Feb 28, 2024SellLXRXCraig B GranowitzSVP, Chief Medical Officer31,265$2.62$1.1B-10.82%+139.00%$81.9K-17.53%Stalk
Feb 28, 2024SellLXRXJeffrey L WadePresident and CFO37,691$2.62$1.1B-10.82%+139.00%$98.8K-7.58%Stalk
Feb 28, 2024SellLXRXLonnel CoatsChief Executive Officer61,371$2.62$1.1B-10.82%+139.00%$160.8K-4.11%Stalk
Nov 16, 2023BuyLXRXLonnel CoatsChief Executive Officer90,000$1.05$1.1B-10.82%+139.00%$94.8K+10.92%Stalk
Nov 10, 2023BuyLXRXLonnel CoatsChief Executive Officer10,000$1.01$1.1B-10.82%+139.00%$10.1K+1.23%Stalk
Sep 14, 2023BuyLXRXJeffrey L WadePresident and CFO10,000$1.38$1.1B-10.82%+139.00%$13.8K+3.93%Stalk
Aug 4, 2023BuyLXRXWendy McdermottVP, Human Resources6,000$1.84$1.1B-10.82%+139.00%$11.0K+26.69%Stalk